Prospective pilot study reveals alterations in gastrointestinal microbiota among patients with rheumatoid arthritis receiving targeted therapies, highlighting medication-driven microbial shifts.
Emerging research suggests that rheumatoid arthritis (RA) is associated with intestinal dysbiosis. This prospective pilot study evaluates changes in intestinal microbial composition in patients with RA initiating treatment with either methotrexate (MTX) or a tumor necrosis factor inhibitor (TNFi).
No takes yet. Share an insight, caveat, or question.
Andréasson et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: